Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06684470 · ClinicalTrials.gov registry record · Early Phase 1
Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
A Early Phase 1 study of Diarrhea and IBS - Irritable Bowel Syndrome, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06684470 is a Early Phase 1 study of Diarrhea and IBS - Irritable Bowel Syndrome that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 156-participant average among 24 other Diarrhea trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06684470, a Early Phase 1 study of Diarrhea and IBS - Irritable Bowel Syndrome, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the added benefit of treating IBS symptoms with a medication called mirtazapine in treating IBS symptoms when paired with a low-FODMAP diet compared to a low-FODMAP diet alone. FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. These are short-chain carbohydrates that can cause digestive distress in some people. You have been asked to take part in this research because you have symptoms of diarrhea-predominant irritable bowel syndrome that may respond to treatment with a combination of a medication called mirtazapine and a low-FODMAP diet.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Mirtazapine
Study Locations (1)
Florida
- Mayo Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2026-12-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06684470
The ClinicalTrials.gov registry entry for NCT06684470 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 24 other Diarrhea trials with a reported enrollment target (87% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06684470 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06684470 about?
NCT06684470 is a clinical study titled "Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator". The purpose of this research is to study the added benefit of treating IBS symptoms with a medication called mirtazapine in treating IBS symptoms when paired with a low-FODMAP diet compared to a low-FODMAP diet alone. FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides, an...
What is the current status of trial NCT06684470?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2024-12-19. Estimated completion is 2026-12-19.
What conditions does trial NCT06684470 study?
This clinical trial studies the following conditions: Diarrhea, IBS - Irritable Bowel Syndrome.
What interventions are being tested in trial NCT06684470?
The interventions under investigation include: Placebo (OTHER), Mirtazapine (DRUG).
Who is sponsoring clinical trial NCT06684470?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06684470 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GI Alpha-Gal Study
RECRUITING · NA
-
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
RECRUITING · Phase 4
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RECRUITING · Phase 1
-
Fecal Microbiota Transplantation for IBS
RECRUITING · Phase 2
-
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
RECRUITING · Phase 1
-
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.